文献速递心脑血管急症重症综合管理与镇静镇痛

全身免疫炎症反应与血管内治疗后再通无效相关

Systemic Immune-Inflammation Response is Associated with Futile Recanalization After Endovascular Treatment.
PubMed 文献 · Neurocrit Care · 2024-02-05
一句话结论急性缺血性卒中血管内治疗成功再通患者中,入院全身免疫炎症指数每升高1个标准差,90天不良功能结局(无效再通)风险增加22.3%(OR 1.223)。

该研究基于前瞻性全国注册研究,纳入血管内治疗后成功再通(mTICI 2b-3)且24小时后维持动脉再通的患者1002例,无效再通定义为90天改良Rankin量表评分3-6分,发生率为50.70%(508例)。入院全身免疫炎症指数(SII)按(血小板计数×中性粒细胞计数)/淋巴细胞计数/100计算,无论作为四分位数还是连续变量,SII均与无效再通显著相关(P<0.05);SII每升高1个标准差,无效再通风险增加22.3%(OR 1.223,95%CI 1.053-1.444,P=0.0093)。SII或SII四分位数与年龄、基线美国国立卫生研究院卒中量表评分、发病至再通时间、mTICI评分之间均未见显著交互作用(交互作用P均>0.05)。作者认为,针对过度活跃的免疫炎症反应进行药物干预可能有助于降低无效再通发生率。

要点

  • 在血管内治疗成功再通(mTICI 2b-3)且24小时维持再通的患者中,无效再通(90天mRS 3-6分)发生率为50.70%(508/1002)。
  • 入院SII按(血小板计数×中性粒细胞计数)/淋巴细胞计数/100计算,无论作为四分位数还是连续变量均与无效再通显著相关(P<0.05)。
  • SII每升高1个标准差,无效再通风险增加22.3%(OR 1.223,95%CI 1.053-1.444,P=0.0093)。
  • SII或SII四分位数与年龄、基线NIHSS评分、发病至再通时间、mTICI评分的交互作用均不显著(交互作用P均>0.05)。
  • 作者认为,针对过度活跃的免疫炎症反应进行药物干预可能有助于降低无效再通发生率。

适用人群与场景

  • 选自前瞻性全国注册研究的急性缺血性卒中患者,血管内治疗后成功再通(mTICI 2b-3)且24小时后维持动脉再通,共1002例。

诊断标准与关键阈值

  • 成功再通定义为改良脑缺血溶栓分级(mTICI)血管造影评分2b-3。
  • 无效再通定义为尽管成功再通,90天改良Rankin量表(mRS)评分3-6分(不良功能结局)。
  • 入院SII计算公式为(血小板计数×中性粒细胞计数)/淋巴细胞计数/100。

研究设计与关键结果

  • 研究类型为基于前瞻性全国注册研究的分析,纳入1002例血管内治疗后成功再通且24小时维持再通的患者。
  • 无效再通发生率为50.70%(508/1002)。
  • SII无论作为四分位数还是连续变量均与无效再通显著相关(P<0.05)。
  • SII每升高1个标准差,无效再通风险增加22.3%(OR 1.223,95%CI 1.053-1.444,P=0.0093)。
  • SII或SII四分位数与年龄、基线NIHSS评分、发病至再通时间、mTICI评分的交互作用均不显著(交互作用P均>0.05)。

证据类型、等级与局限

  • 证据类型:基于前瞻性全国注册研究的分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,早期SII升高与血管内治疗患者无效再通风险增加相关,针对过度活跃的免疫炎症反应进行药物干预可能有助于降低无效再通发生率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Frequent incidence of futile recanalization decreases the benefit of endovascular treatment (EVT) in acute ischemic stroke. We hypothesized that the inflammation and immune response after ischemic are associated with futile recanalization. We aimed to investigate the correlation of admission systemic immune-inflammation index (SII) with futile recanalization post EVT.

METHODS: Patients with successful recanalization (modified Thrombolysis in Cerebral Ischemia angiographic score 2b-3) and maintained artery recanalized after 24 h of EVT were chosen from a prospective nationwide registry study. Futile recanalization was defined as a poor functional outcome (modified Rankin Scale score 3-6) at 90 days, irrespective of a successful recanalization. At admission, SII was calculated as (platelet count × neutrophil count)/lymphocyte count/100. Logistic regression analysis helped to test the relationship of SII with futile recanalization.

RESULTS: Among the 1,002 patients included, futile recanalization occurred in 508 (50.70%). No matter whether tested as quartiles or continuous variables, SII was significantly associated with futile recanalization (P < 0.05), and for every one standard deviation increase of SII, the risk of futile recanalization elevated by 22.3% (odds ratio 1.223, 95% confidence interval 1.053-1.444, P = 0.0093). Moreover, no significant interactions could be observed between SII or SII quartiles and age, baseline National Institutes of Health Stroke Scale scores, onset-to-recanalization time, and modified Thrombolysis in Cerebral Ischemia angiographic scores (all P for interaction > 0.05).

CONCLUSIONS: Early SII elevation was associated with an increased risk of futile recanalization among patients with EVT. Our results indicated that therapeutic drug targeting hyperreactive immune-inflammation response might be helpful for reducing the incidence of futile recanalization.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Chen G, Wang A, Zhang X, et al. Systemic Immune-Inflammation Response is Associated with Futile Recanalization After Endovascular Treatment. Neurocrit Care. 2024. PMID: 38316736. doi:10.1007/s12028-023-01930-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。